EcoDrugPlus

Histone Deacetylase 8

Ensembl ID : ENSTNIG00000005782
Gene Symbol: HDAC8
2 Cross references
205 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSTNIG00000015827
Gene Symbol: HCAR1
3 Cross references
230 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSTNIG00000013712
Gene Symbol: HCN4
3 Cross references
213 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSTNIG00000011958
Gene Symbol: HCN4
2 Cross references
221 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSTNIG00000016567
Gene Symbol: HCRTR2
2 Cross references
203 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSTNIG00000015917
Gene Symbol: IKBKB
2 Cross references
199 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSTNIG00000014905
Gene Symbol: INSRA
2 Cross references
213 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSTNIG00000015518
Gene Symbol: INSRB
2 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSTNIG00000019227
Gene Symbol: IGF1RA
2 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSTNIG00000011921
Gene Symbol: IGF1RB
2 Cross references
203 Possible Orthologues:

Integrin Beta 3a

Ensembl ID : ENSTNIG00000011722
Gene Symbol: ITGB3A
2 Cross references
201 Possible Orthologues:

Integrin Beta 3b

Ensembl ID : ENSTNIG00000011575
Gene Symbol: ITGB3B
2 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).